Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06313801

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

The Single-center Randomized Study Comparison of Safety and Effectiveness of the First Line of Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions in Primary Gastric Cancer With Isolated Peritoneal Carcinomatosis.

Sponsor: Nizhny Novgorod Regional Clinical Oncology Center

Conditions Gastric Cancer

Interventions Calcium folinate Diagnostic laparoscopy Docetaxel Fluorouracil Oxaliplatin dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)).

Updated 5 times since 2024 Last updated: Nov 18, 2025 Started: Jan 19, 2023 Primary completion: Jul 1, 2026 Completion: Sep 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric Cancer, this trial is actively recruiting participants. The trial is conducted by Nizhny Novgorod Regional Clinical Oncology Center and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE2
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nizhny Novgorod Regional Clinical Oncology Center

Data source: Nizhny Novgorod Regional Clinical Oncology Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nizhny Novgorod, Russia